Stockhub

ValiRx plc: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

14 August 2022

10 August 2022

  • curprev 19:1719:17, 10 August 2022‎ Paris talk contribs‎ 921 bytes +921‎ Created page with "ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial fo..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/ValiRx_plc’